Publications

NYX-2925

2022

NYX-2925, a novel N-methyl-D-aspartate Receptor Positive Allosteric Modulator, Showed Antinociceptive Activity in Functional Neuroimaging Evaluations Correlated with Improved Patient-Reported Pain and Fibromyalgia Symptoms

Recent in vivo advances of spirocyclic scaffolds for drug discovery

2021

NYX-2925, a novel, non-opioid, small-molecule modulator of the N-Methyl-D-Aspartate Receptor (NMDAR), demonstrates potential to treat chronic, supraspinal centralized pain conditions

2019

NYX-2925 impacts functional and chemical neuroimaging biomarkers and patient-reported outcomes of pain in patients with fibromyalgia

NYX-2925, a novel NMDA receptor modulator, improves chronic pain and its affective state in rats with paclitaxel-induced neuropathy

The novel NMDA receptor modulator, NYX-2925, enhances NMDAR-mediated current and LTP, induces changes in cell intrinsic properties, and alters firing properties in layer 5 pyramidal neurons of rat mPFC

NYX-2925, a novel NMDA receptor modulator, improves chronic pain and its affective state in rats with paclitaxel-induced neuropathy

NYX-2925 induces metabotropic NMDAR signaling that enhances synaptic NMDAR and AMPAR

NMDAR activation regulates the daily rhythms of sleep and mood

A translational EEG-based approach to assess modulation of long-lasting NMDAR-dependent synaptic plasticity

2018

NYX-2925 is a Novel N-Methyl-D-aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain

NYX-2925, A Novel N-methyl-D-aspartate Receptor Modulator: A First-in-Human, Randomized, Double-blind Study of Safety and Pharmacokinetics in Adults

NYX-2925 facilitates auditory-evoked long-term potentiation in rats: a translational approach for measuring NMDA receptor-mediated synaptic plasticity

Enhancement of synaptic plasticity by NYX-2925: Sleep cycle EEG studies in rats

Preclinical Through Early-Stage Clinical Development of a Novel NMDA Receptor Modulator, NYX-2925

NYX-2925 Reverses the Decrease in Hedonic Ultrasonic Vocalization and the Increase in Aversive Vocalization Observed With Cci-Induced Neuropathic Pain in Rats

NYX-2925 Improves Both Pain and Its Affective States in the Rat Chronic Constriction Injury Model of Neuropathic Pain

NYX-2925 re-normalizes synaptic-plasticity associated protein expression in rat mPFC: a potential mechanism for the compound’s analgesic effect in neuropathic pain

NYX-2925, a novel NMDA receptor modulator, renormalizes synaptic plasticity associated cortical protein expressions in rats with CCI: a potential mechanism for the compound’s analgesic effect in neuropathic pain

The NMDA Receptor Modulator NYX-2925 Shows Therapeutic Potential in Preclinical Models for the Treatment of Neuropathic Pain

NYX-2925 facilitates auditory-evoked long-term potentiation in rats: a translational approach for measuring NMDA receptor-mediated synaptic plasticity

The novel NMDA receptor modulator NYX-2925 enhances dendritic spine autonomous structural and functional plasticity in vitro

2017

NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory

NYX-2925, a Novel NMDA Receptor Modulator, Shows Efficacy in Neuropathic Pain that is NMDA and AMPA Receptor Dependent and Appears to Be Driven through Brain, but NOT Spinal Circuitry

The NMDA Receptor Modulator NYX-2925 Shows Therapeutic Potential in Preclinical Models for the Treatment of Neuropathic Pain

2016

JY-515,317 (NYX-2925) is a NMDA receptor modulator with glycine site partial agonist-like properties: in vitro and in vivo pharmacology

JY-515,317 (NYX-2925), an NMDA receptor modulator with glycine site partial agonist-like properties, shows therapeutic potential for the treatment of neuropathic pain

JY-515,317 (NYX-2925), a NMDA receptor modulator with glycine site partial agonist-like properties, has neuroprotective effects in a rat model of blast-induced traumatic brain injury

NYX-2925 is a NMDA receptor modulator with glycine site partial agonist-like properties: in vitro and in vivo characterization

NYX-2925, an NMDA receptor modulator with glycine site partial agonist-like properties, induces rapid and long-lasting analgesic effect in multiple rat models of neuropathic pain